On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.
Copaxone also continues to be a major asset for Teva despite the expiry of its patent and the subsequent entry of generic competition for its 20 mg and 40 mg formulations.
In its fourth-quarter earnings presentation, Teva Pharmaceutical highlighted Ajovy’s normalized weekly TRx (total prescription) count of 6,017 as of the end of January 11, which accounted for a normalized TRx share of 19%. The company has also estimated that 11% of Ajovy’s TRx count has been written for quarterly dosing.
At the end of December 2018, the drug accounted for 28% of the company’s new-to-brand share, a gradual rise from 3% at the end of September, 14% at the end of October, and 27% at the end of November. By the end of January 11, 2019, Ajovy had been prescribed by 6,400 healthcare practitioners. Teva Pharmaceutical and Regeneron’s (REGN) Ajovy is currently competing with Amgen (AMGN) and Novartis’s (NVS) Aimovig and Eli Lilly and Company’s (LLY) Emgality in the migraine prophylaxis market.
In its fourth-quarter earnings presentation, Teva Pharmaceutical revealed that the number of unique patients who had been prescribed Austedo in the fourth quarter was 10,500, a YoY (year-over-year) rise of 156.10% and a sequential rise of 38.16%. In addition to Huntington’s disease, Austedo is focused on treating the underexplored tardive dyskinesia segment in the United States, which has a prevalence of 0.5 million patients.
In 2018, Copaxone reported total revenue of $1.70 billion in the US market. According to the company’s fourth-quarter earnings conference call, Copaxone continues to be a major multiple sclerosis drug in the United States despite its reporting a 20% lower TRx count and close to 25% lower pricing on a YoY basis. The downward trend in the United States is expected to continue, thereby reducing Copaxone’s revenue even further in 2019. Copaxone’s revenue fall was less steep in Europe than in the United States. The drug accounts for a 75% volume share in Europe and is expected to report a gradual fall in its share in 2019 and 2020.
Next, we’ll discuss trends for Teva Pharmaceutical’s generics business.